Pith. sign in

REVIEW 2 major objections 7 minor 17 references

Learning Clinical-Trial Strategy: Offline Policy Training for Decision Agents

T0 review · 2 major / 7 minor · reviewed 2026-08-05 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read Reward-weighted behavioral cloning trained on historical oncology decisions beats frontier tool-using agents at predicting next clinical-trial portfolios.

desk verdict A genuinely useful new benchmark, but the post-cutoff 'clean' result trains on rewards that postdate the test cutoff, so the headline gap is overstated. read the letter →

arxiv 2608.03606 v1 pith:LNEKJSYU submitted 2026-08-04 cs.AI cs.LG

William Bolton , Philip Torr This is my paper · ORCID
classification cs.AIcs.LG
keywords offlinereinforcementlearningclinicaltrialstrategybehavioralcloningreward-weightedoncologydrugdevelopmentportfoliopredictionLLMagentstemporaldataset
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

The paper tries to establish that clinical-trial strategy—deciding which trials a sponsor should launch next for an oncology drug—is a learnable offline decision problem, not just a knowledge-retrieval task for large language models. It assembles a temporal dataset of 881 decision episodes from 31.7k public records and uses it to fine-tune a 7B language model under four training objectives. On the contamination-clean post-August-2025 holdout, the simplest outcome-weighted imitation objective reaches 46.2% indication F1 and 14.2% strict F1, versus 25.0% and 2.1% for the best tool-using frontier agent on each metric. If this is right, retrospective public data on drug development carries a learnable strategic signal, and offline policy training could support portfolio planning rather than relying on parametric knowledge.

What carries the argument

The load-bearing mechanism is the offline decision episode: at each six-month window, a state containing only pre-decision public evidence is mapped to a 14-field structured trial portfolio, and each launched trial receives a retrospective reward r_i = 2a_i - f_i + log(1 + rev_i) that credits FDA approvals and attributed revenue back to the window in which the pivotal trial was launched. Reward-weighted behavioral cloning converts this per-trial reward into clipped sampling weights and trains the same Qwen-2.5-7B backbone with QLoRA, so high-reward windows are oversampled. An approval linker that matches NCT identifiers and trial acronyms in FDA review PDFs is what makes this credit assignme

What would settle it

Manually reconstruct the launch portfolios for a random sample of 50 program-windows directly from ClinicalTrials.gov registration dates and FDA review documents, then recompute RW-BC's indication and strict F1 on those hand-verified windows; if the hand-built portfolios differ materially from the dataset's 1,956 launch actions, the reported ranking could be an artifact of label error rather than a real difference in planning ability.

Watch

Extended reading notes

Core claim

The central discovery is that reweighting behavioral cloning by a per-trial reward built from FDA approval linkage, trial failure, and attributed revenue produces the strongest predictor of the next six-month trial portfolio, and that this predictor transfers across held-out drugs, sponsors, drug classes, and temporal windows. The effect is cleanest where pretraining contamination is impossible: on the post-August-2025 subset, RW-BC reaches 46.2% indication F1 and 14.2% strict F1 against 25.0% and 2.1% for the best tool agent on each metric, with the strict-F1 gap having a bootstrap CI excluding zero. The paper argues the improvement comes from learning a decision mapping from outcome-weight

Load-bearing premise

The whole comparison rests on the dataset correctly identifying which trials were actually launched in each six-month window and correctly crediting later FDA approvals back to the trials that supported them; if records are parsed incompletely or approvals attach to the wrong trial, every model's score is being measured against a faulty ground truth.

Editorial extensions

If this is right

  • Fine-tuning a small open-weight model on historical decision episodes can teach it to assemble the correct indication, phase, and strategy jointly, instead of just naming the right disease the way the untrained base model does.
  • Offline-trained models keep most of their score in autoregressive rollout where they condition on their own previous predictions, while frontier agents degrade more sharply.
  • Reward-weighted behavioral cloning outperforms value-based implicit Q-learning at 881 episodes, consistent with prior offline-RL findings that simple imitation reweighted by returns can beat value-based methods when data are limited.
  • Naively composing offline policy with agent-retrieved evidence improved RW-BC to 59.0% indication F1 and 18.6% strict F1 on the post-cutoff subset, pointing to retrieval-augmented offline policies as a near-term direction.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • Because the approval-linkage term dominates the reward (correlation 0.98), the method is effectively learning to imitate decisions that later became pivotal approvals; a causal counterfactual reward could push beyond this retrospective association.
  • The same dataset pipeline could be extended to non-oncology therapeutic areas or to phase I/II decisions, where approval-linked rewards are sparser and would need surrogate outcome signals.
  • The gap between frontier agents' design knowledge (decent field-match when they identify the right trial) and their decision targeting suggests the bottleneck is strategic action selection, not factual knowledge—so retrieval-heavy agent scaffolds alone are unlikely to close it.
  • Precise reward tuning matters less than the approval-linkage signal itself, since dropping reward terms moves training weights only slightly; future work could therefore focus on cleaning and expanding the ground-truth launch and approval linkage data rather than on more sophisticated objectives.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

2 major / 7 minor

Summary. The paper frames oncology clinical-trial strategy as an offline decision-making problem: at each six-month window, an agent predicts the next trial portfolio of a drug program from date-gated evidence. The authors construct a dataset of 881 decision episodes across 45 programs from 31.7k public records (ClinicalTrials.gov, Drugs@FDA, SEC filings, CMS, SEER), compare four offline objectives (BC, RW-BC, LR-BC, IQL) against four frontier LLM tool agents on shared retrieval scaffolds across drug, sponsor, drug-class, and temporal splits, and report that fine-tuned offline models, especially RW-BC, outperform the agents. The headline result is on the post-August 2025 'contamination-clean' holdout, where RW-BC reaches 46.2% indication F1 and 14.2% strict F1 versus 25.0% and 2.1% for the best tool agents.

Significance. If the result holds, the paper provides a valuable benchmark and evidence that structured offline training on historical trial data can transfer to next-trial-portfolio prediction, complementing prior work on trial-outcome prediction. The strengths are substantial: a reproducible dataset and code release, date-gated state construction, a structured action schema, multiple held-out generalization axes, and an honest discussion of limitations (small post-cutoff sample, associational rewards, schema abstraction). However, the central comparison is compromised by a temporal-leakage issue in the reward labels used to weight training examples, which affects the 'contamination-clean' claim. Because the paper is fundamentally a benchmark paper, the absence of validation of the ground-truth construction pipeline is also a serious gap. With these addressed, the work could make a useful contribution; as written, the main quantitative claim is not yet fully supported.

major comments (2)
  1. [§2.4, Eq. (1); §2.2; Appendix A.5] The per-trial reward ri = 2ai − fi + log(1 + revi) is computed from FDA approvals and peak revenue that can be realized well after the decision window. For the post-August 2025 holdout, nothing in Appendix A.5 truncates reward events at the cutoff: training windows with decision dates before August 2025 can be weighted by outcomes observed after August 2025, injecting information that would be unavailable in a prospective deployment at that cutoff. The LLM agents receive no such outcome labels, making the comparison asymmetric. Since the headline 46.2 vs 25.0 and 14.2 vs 2.1 numbers are on the 'contamination-clean' subset, this leakage undermines the clean-holdout claim. Please either truncate reward realizations at the cutoff (or at each decision date) and retrain, or reword the claim and add an explicit caveat that the training rewards include post-cutoff information.
  2. [Appendix A.2–A.4] The benchmark's validity rests on the accuracy of the approval linker and trial-date extraction, but no validation of these components is reported. No precision/recall or manual audit is given for NCT/acronym matching, no check that the sponsor-scoped fallback rules do not misattribute approvals, and no comparison against an independent source (e.g., FDA labels or company disclosures) is provided. Because every method is scored against the same ground-truth portfolios and rewards, systematic linker errors would bias all comparisons. Please add a validation subsection with, at minimum, a hand-checked sample of trials and approvals and a sensitivity analysis on the reward definition.
minor comments (7)
  1. [Table 1] The dagger before 'post-Aug 2025' is unexplained; either define it or remove it.
  2. [Figure 1] The caption says 'windows-weighted means' but the weighting is not defined. Clarify whether this is an unweighted mean over windows or weighted by number of trials/portfolio size.
  3. [§3] The statement that 'every fine-tuned model beats all four frontier agents on indication and field-match (P≈0.99–1.0)' should report the statistical test used and whether any multiple-comparison correction was applied across the eight splits.
  4. [Appendix B.3] The R² values for state→reward (0.49) and decision→reward (0.025) are reported without details on the regression specification, features, or cross-validation. Please provide enough detail to interpret these numbers.
  5. [Appendix A.10] The claim that ranking is invariant for τ∈[0.50,0.75] would be better supported by a small sensitivity table rather than a one-line statement.
  6. [Abstract] The '27k structured fields to predict' is not defined in the main text; please clarify what counts as a field (e.g., each trial field across all episodes? per trial?).
  7. [§2.4 and Appendix A.7] LR-BC regresses onto the same rule-based reward target used by RW-BC; this is disclosed in B.3, but the main text should state this early so readers do not treat LR-BC as an independent learned-reward signal.

Circularity Check

1 steps flagged · score 1.0 of 10

Minor disclosed redundancy in LR-BC; the central benchmark is otherwise self-contained.

  1. self definitional [Section 2.4; Appendix A.7; Appendix B.3]
    "Rather than the fixed coefficients of Eq. 1, we learn the reward (Appendix A.7) by regressing trial-design features onto the same per-trial outcome target, so the model infers the objective from the structure of the trials instead of from a rule-based formula. ... Learned-reward weighting fits a regression whose target is the specified reward itself, so its ceiling is reward-weighted cloning and the approximation only adds variance."

    The learned-reward baseline (LR-BC) is constructed by fitting a regression to the same per-trial reward target (Eq. 1) that defines RW-BC's sampling weights. Thus LR-BC's 'learned' reward is a noisy re-encoding of the rule-based reward rather than an independent objective; any comparison between LR-BC and RW-BC is partly by construction. The paper discloses this in Appendix B.3, and it does not bear on the headline RW-BC-versus-agent result, so the circularity is minor and non-load-bearing.

full rationale

The central result is a held-out benchmark: eight splits hold out entire drugs, sponsors, drug classes, or temporal windows, and every method is scored by F1 against historical ground-truth portfolios. No fitted parameter is renamed as a prediction; the reward-weighted and IQL objectives use the same outcome reward, but the evaluation does not use rewards and the test actions are not constructed from any model output. There are no load-bearing self-citations: the cited offline-RL and IQL methods are external and standard. The only self-definitional element is LR-BC, whose learned target is Eq. 1; the paper explicitly concedes its ceiling in Appendix B.3, so it is a disclosed ablation, not a hidden derivation. The paper also flags that rewards are retrospective associations and that the post-August-2025 subset is small (n=24); these limit interpretation but are not circular. The post-August-2025 'contamination-clean' label is best read as a correctness risk rather than circularity: rewards for pre-cutoff training windows may incorporate approvals or revenue dated after the cutoff, so the temporal split may leak outcome information into the trained policies. However, that is an external-validity threat and not a reduction of the test predictions to the training inputs by construction.

Assumptions & free parameters 4 free parameters · 4 assumptions · 0 invented entities

The central claims rest mainly on two domain assumptions: that historical trial-launch decisions are a useful target to imitate, and that the rule-based reward (approval, failure, revenue) is a valid training signal. Both are acknowledged by the authors as limiting. There are no invented physical or conceptual entities beyond the dataset and action schema. The free parameters are standard hyperparameters plus the reward coefficients, which are not fitted to the test set but are nevertheless hand-specified.

free parameters (4)
  • Reward coefficients in Eq. 1 = a_i weight = 2, failure penalty = -1, log-revenue coefficient = 1
    Hand-chosen weights defining the per-trial reward. The reward is central to RW-BC and IQL; the paper's own ablation shows the approval term (weight 2) dominates.
  • Clipping bounds for sampling weights = 0.5 offset, lower 0.1, upper 3.0
    Hand-set in Eq. 2 to bound oversampling. These affect the training distribution of RW-BC, LR-BC, and IQL.
  • IQL hyperparameters = expectile tau=0.7, discount gamma=0.95, inverse temperature beta=0.5
    Chosen for the value-based objective. The paper reports robustness across a sweep, so these are not finely tuned, but they are still free choices.
  • Embedding matching threshold = tau=0.62
    Threshold for matching free-text fields during evaluation. The paper reports the ranking is invariant over [0.50, 0.75], but the choice is ad hoc.
assumptions (4)
  • domain assumption Historical sponsor decisions are a meaningful learning target
    The model is trained to imitate realized trial portfolios. The paper acknowledges these are 'one realized decision among multiple plausible counterfactuals' and that private information affects decisions, so this is an assumption about the usefulness of the imitation signal.
  • domain assumption The reward function (Eq. 1) is a valid proxy for the value of a trial-launch decision
    The paper states rewards are 'retrospective associations, not causal estimates' and that unobserved confounders prevent separating decision quality from program trajectory. This is a strong assumption that the weighting signal improves the policy beyond BC.
  • domain assumption The public data sources provide complete coverage of trial launches and approvals
    The entire benchmark depends on the completeness and correctness of ClinicalTrials.gov, FDA reviews, SEC filings, and other sources. If public records are incomplete, the ground-truth labels are wrong. The paper provides no external validation of coverage.
  • standard math Standard offline RL and supervised learning assumptions
    BC, advantage-weighted regression, and IQL rely on standard theory (e.g., expectile regression, clipped importance weights) that is not re-derived here.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Learning Clinical-Trial Strategy: Offline Policy Training for Decision Agents." pith.science (2026). https://pith.science/paper/LNEKJSYU

@misc{pith2026260803606,
  author       = {Pith},
  title        = {Pith review of: Learning Clinical-Trial Strategy: Offline Policy Training for Decision Agents},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/LNEKJSYU}},
  note         = {Machine review of arXiv:2608.03606}
}
read the original abstract

Clinical development is sequential decision-making under uncertainty, where a sponsor must plan a portfolio of experiments from heterogeneous evidence. We study this setting by framing oncology clinical development as an offline decision-making problem in which an agent predicts the next six-month trial portfolio of an oncology drug program from information available at the decision date. To support this, we construct a temporal dataset that combines 31.7k heterogeneous public data records, including trial registries, regulatory reviews, sponsor filings, utilization data, and epidemiology, into 881 offline decision episodes across 45 historical programs. We compare four offline objectives: behavioral cloning, reward-weighted behavioral cloning, learned-reward training, and value-based implicit Q-learning against four frontier LLM agents that share a common date-gated retrieval scaffold across held-out drug, sponsor, drug-class, and temporal splits. Models trained offline outperform the non-fine-tuned baselines, particularly in the post-August 2025 contamination-clean holdout. Reward-weighted behavioral cloning performs the best, obtaining 46.2% indication F1 and 14.2% strict F1 against 25.0% and 2.1%, respectively, for the best-performing tool agent on each metric. These results suggest that structured offline learning can teach agents to plan clinical experiments.

Figures

Figures reproduced from arXiv: 2608.03606 by the authors.

Figure 1
Figure 1. shows results on both the full held-out set and the contamination-free post-August 2025 subset, on which no model could have memorized the decisions. The offline￾trained models outperform the non-fine-tuned baselines, particularly on the post-August 2025 subset, where the strongest model, reward-weighted behavioral cloning (RW￾BC), reaches 46.2% indication F1 and 14.2% strict F1 versus 25.0% and 2.1%, respectively, … view at source ↗
Figure 2
Figure 2. An example trial conforming to the action schema. Real predictions and ground-truth trials follow this shape exactly. The surrounding portfolio is a list of one to ten such objects. A.2. Primary data sources and auxiliary corpus The benchmark state, action, and reward are constructed from five primary public-source streams. ClinicalTrials.gov provides trials, eligibility criteria, outcomes, and trial timing. Drugs@F… view at source ↗
Figure 3
Figure 3. Indication F1 versus Strict F1 across methods on the full held-out set (n=432). Higher and more rightward is better. The offline-trained models (diamonds) occupy the upper-right, scoring well on both axes; the tool-using agents (squares) sit lower; the non-fine-tuned Qwen-2.5-7B reaches high Indication F1 but near-zero Strict F1 (it names the right disease without the matching structured trial), and the random basel… view at source ↗

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

17 extracted references · 11 canonical work pages

  1. [1]

    When does return-conditioned supervised learning work for offline reinforcement learning? In Advances in Neural Information Processing Systems (NeurIPS), 2022

    Brandfonbrener, D., Bietti, A., Buckman, J., Laroche, R., and Bruna, J. When does return-conditioned supervised learning work for offline reinforcement learning? In Advances in Neural Information Processing Systems (NeurIPS), 2022

    work page 2022

  2. [2]

    Trialbench: Multi-modal ai-ready datasets for clinical trial prediction

    Chen, J., Hu, Y., Cai, M., Lu, Y., Wang, Y., Cao, X., Lin, M., Xu, H., Wu, J., Cao, X., et al. Trialbench: Multi-modal ai-ready datasets for clinical trial prediction. Scientific Data, 12 0 (1): 0 1564, 2025

    work page 2025

  3. [3]

    Decision transformer: Reinforcement learning via sequence modeling

    Chen, L., Lu, K., Rajeswaran, A., Lee, K., Grover, A., Laskin, M., Abbeel, P., Srinivas, A., and Mordatch, I. Decision transformer: Reinforcement learning via sequence modeling. Advances in neural information processing systems, 34: 0 15084--15097, 2021

    work page 2021

  4. [4]

    RvS : What is essential for offline RL via supervised learning? In International Conference on Learning Representations (ICLR), 2022

    Emmons, S., Eysenbach, B., Kostrikov, I., and Levine, S. RvS : What is essential for offline RL via supervised learning? In International Conference on Learning Representations (ICLR), 2022

    work page 2022

  5. [5]

    M., and Sun, J

    Fu, T., Huang, K., Xiao, C., Glass, L. M., and Sun, J. Hint: Hierarchical interaction network for clinical-trial-outcome predictions. Patterns, 3 0 (4), 2022

    work page 2022

  6. [6]

    Biomni: A general-purpose biomedical ai agent

    Huang, K., Zhang, S., Wang, H., Qu, Y., Lu, Y., Roohani, Y., Li, R., Qiu, L., Li, G., Zhang, J., et al. Biomni: A general-purpose biomedical ai agent. biorxiv, 2025

    work page 2025

  7. [7]

    Offline reinforcement learning as one big sequence modeling problem

    Janner, M., Li, Q., and Levine, S. Offline reinforcement learning as one big sequence modeling problem. Advances in neural information processing systems, 34: 0 1273--1286, 2021

    work page 2021

  8. [8]

    S., Chen, F., Gong, C., Bracken-Clarke, D., Xue, E., Yang, Y., Sun, J., and Lu, Z

    Jin, Q., Wang, Z., Floudas, C. S., Chen, F., Gong, C., Bracken-Clarke, D., Xue, E., Yang, Y., Sun, J., and Lu, Z. Matching patients to clinical trials with large language models. Nature communications, 15 0 (1): 0 9074, 2024

    work page 2024

Show all 17 references
  1. [9]

    Offline reinforcement learning with implicit q-learning

    Kostrikov, I., Nair, A., and Levine, S. Offline reinforcement learning with implicit q-learning. arXiv preprint arXiv:2110.06169, 2021

    2021 arXiv

  2. [10]

    When should we prefer offline reinforcement learning over behavioral cloning? In International Conference on Learning Representations (ICLR), 2022

    Kumar, A., Hong, J., Singh, A., and Levine, S. When should we prefer offline reinforcement learning over behavioral cloning? In International Conference on Learning Representations (ICLR), 2022. arXiv:2204.05618

    2022 arXiv

  3. [11]

    Offline reinforcement learning: Tutorial, review, and perspectives on open problems

    Levine, S., Kumar, A., Tucker, G., and Fu, J. Offline reinforcement learning: Tutorial, review, and perspectives on open problems. arXiv preprint arXiv:2005.01643, 2020

    2005 arXiv

  4. [12]

    Awac: Accelerating online reinforcement learning with offline datasets

    Nair, A., Gupta, A., Dalal, M., and Levine, S. Awac: Accelerating online reinforcement learning with offline datasets. arXiv preprint arXiv:2006.09359, 2020

    2006 arXiv

  5. [13]

    B., Kumar, A., Zhang, G., and Levine, S

    Peng, X. B., Kumar, A., Zhang, G., and Levine, S. Advantage-weighted regression: Simple and scalable off-policy reinforcement learning. arXiv preprint arXiv:1910.00177, 2019

    1910 arXiv

  6. [14]

    F., Maximo, M

    Prudencio, R. F., Maximo, M. R., and Colombini, E. L. A survey on offline reinforcement learning: Taxonomy, review, and open problems. IEEE transactions on neural networks and learning systems, 35 0 (8): 0 10237--10257, 2023

    2023

  7. [15]

    Agentclinic: a multimodal agent benchmark to evaluate ai in simulated clinical environments

    Schmidgall, S., Ziaei, R., Harris, C., Reis, E., Jopling, J., and Moor, M. Agentclinic: a multimodal agent benchmark to evaluate ai in simulated clinical environments. arXiv preprint arXiv:2405.07960, 2024

    2024 arXiv

  8. [16]

    and Kim, Y

    Shin, W. and Kim, Y. Guide to control: Offline hierarchical reinforcement learning using subgoal generation for long-horizon and sparse-reward tasks. In IJCAI, pp.\ 4217--4225, 2023

    2023

  9. [17]

    T., Reed, S., Shahriari, B., Siegel, N., Merel, J., Gulcehre, C., Heess, N., and de Freitas, N

    Wang, Z., Novikov, A., Zolna, K., Springenberg, J. T., Reed, S., Shahriari, B., Siegel, N., Merel, J., Gulcehre, C., Heess, N., and de Freitas, N. Critic regularized regression. In Advances in Neural Information Processing Systems (NeurIPS), 2020

    2020

Pith tools

Reviewed August 5, 2026 · model on record in the stance chip above.